Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 2/20 | 0.79 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.79 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.79 |
| ▸ | TUBB1 | Q9H4B7 | 14/20 | 0.76 |
| ▸ | TUBB4A | P04350 | 9/20 | 0.76 |
| ▸ | TUBB | P07437 | 9/20 | 0.76 |
| ▸ | TUBA3C | P0DPH7 | 9/20 | 0.76 |
| ▸ | TUBA1B | P68363 | 9/20 | 0.76 |
| ▸ | TUBA4A | P68366 | 9/20 | 0.76 |
| ▸ | TUBB4B | P68371 | 9/20 | 0.76 |
| ▸ | TUBB3 | Q13509 | 9/20 | 0.76 |
| ▸ | TUBB2A | Q13885 | 9/20 | 0.76 |
| ▸ | TUBB8 | Q3ZCM7 | 9/20 | 0.76 |
| ▸ | TUBA3E | Q6PEY2 | 9/20 | 0.76 |
| ▸ | TUBA1A | Q71U36 | 9/20 | 0.76 |
| ▸ | TUBA1C | Q9BQE3 | 9/20 | 0.76 |
| ▸ | TUBB6 | Q9BUF5 | 9/20 | 0.76 |
| ▸ | TUBB2B | Q9BVA1 | 9/20 | 0.76 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.70 |
| ▸ | NQO2 | P16083 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4608533 | 1.00 | CYP1A1 (0.79) | CYP1A1CYP1A2CYP1B1TUBB1TUBB4A | |
| SCHEMBL4659251 | 0.93 | TUBB1 (0.85) | CYP1A1CYP1A2CYP1B1TUBB1TUBB4A | |
| SCHEMBL6896671 | 0.93 | TUBB1 (0.85) | CYP1A1CYP1A2CYP1B1TUBB1TUBB4A | |
| SCHEMBL631213 | 0.93 | TUBB1 (0.85) | CYP1A1CYP1A2CYP1B1TUBB1TUBB4A | |
| SCHEMBL2622571 | 0.90 | CYP1A1 (0.67) | CYP1A1CYP1A2CYP1B1TUBB1TUBB4A | |
| SCHEMBL2357479 | 0.89 | ABL1 (0.69) | CYP1A1CYP1A2CYP1B1TUBB1TUBB4A | |
| SCHEMBL1393611 | 0.89 | CYP1A1 (1.00) | CYP1A1CYP1A2CYP1B1TUBB1TUBB4A | |
| SCHEMBL6702450 | 0.89 | CYP1A1 (0.69) | CYP1A1CYP1A2CYP1B1TUBB1TUBB4A | |
| SCHEMBL2357485 | 0.89 | ABL1 (0.69) | CYP1A1CYP1A2CYP1B1TUBB1TUBB4A | |
| SCHEMBL1393613 | 0.89 | CYP1A1 (1.00) | CYP1A1CYP1A2CYP1B1TUBB1TUBB4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1654210-B1 | STILBENE DERIVATIVES AND THEIR USE IN MEDICAMENTS | SZEKERES THOMAS (AT) | 2008-07-30 | — | — | EP | claimed |
| US-20070191627-A1 | Stilbene derivatives and their use in medicaments | SZEKERES THOMAS | 2007-08-16 | — | — | US | claimed |
| EP-1654210-A2 | STILBENE DERIVATIVES AND THEIR USE IN MEDICAMENTS | Szekeres, Thomas (AT) | 2006-05-10 | — | — | EP | claimed |
| WO-2005102298-A1 | MEDICAL SUBSTANCE MIXTURES CONTAINING RESVERATROL OR RESVERATROL-DERIVATIVES, IN ADDITION TO THE USE THEREOF IN THE PRODUCTION OF MEDICAMENTS | SZEKERES THOMAS (AT) | 2005-11-03 | — | — | WO | claimed |
| WO-2005016860-A2 | STILBENE DERIVATIVES AND THEIR USE IN MEDICAMENTS | SZEKERES THOMAS (AT) | 2005-02-24 | — | — | WO | claimed |
| EP-1654210-B1 | STILBENE DERIVATIVES AND THEIR USE IN MEDICAMENTS | SZEKERES THOMAS (AT) | 2008-07-30 | — | — | EP | disclosed |
| US-20070191627-A1 | Stilbene derivatives and their use in medicaments | SZEKERES THOMAS | 2007-08-16 | — | — | US | disclosed |
| EP-1654210-A2 | STILBENE DERIVATIVES AND THEIR USE IN MEDICAMENTS | Szekeres, Thomas (AT) | 2006-05-10 | — | — | EP | disclosed |
| US-7026518-B2 | Resveratrol analogs | LAILA IMPEX (IN) | 2006-04-11 | — | — | US | disclosed |
| WO-2005016860-A2 | STILBENE DERIVATIVES AND THEIR USE IN MEDICAMENTS | SZEKERES THOMAS (AT) | 2005-02-24 | — | — | WO | disclosed |
| US-20040209951-A1 | Novel resveratrol analogs | LAILA IMPEX (IN) | 2004-10-21 | — | — | US | disclosed |
| WO-2004000302-A1 | NOVEL RESVERATROL ANALOGS | GOKARAJU GANGA RAJU (IN) | 2003-12-31 | — | — | WO | disclosed |
| US-4533505-A | REACTION OF ETHYLENE IWITH ACID HALIDES IN THE PRESENCE OF A BASE AND A PALLADIUM CATALYST | CIBA-GEIGY CORPORATION (US) | 1985-08-06 | — | — | US | disclosed |
| EP-0062005-B1 | PROCESS FOR THE MANUFACTURE OF STYRENE AND/OR STILBENE DERIVATIVES | CIBA-GEIGY AG (CH) | 1985-06-26 | — | — | EP | disclosed |
| EP-0062005-A1 | Process for the manufacture of styrene and/or stilbene derivatives | CIBA-GEIGY AG (CH) | 1982-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209951-A1 | Novel resveratrol analogs | HRH1, CBR1, CBR3 | CYP1A1 505/4885CYP1A2 1908/4885CYP1B1 362/4885 |
| US-20070191627-A1 | Stilbene derivatives and their use in medicaments | PTGS2, PTGS1, PTGER2 | CYP1A1 371/4885CYP1A2 167/4885CYP1B1 275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.